Bad company? 'Industry' brand turns doctors off
This article was originally published in Scrip
Physicians are half as likely to prescribe drugs studied in industry-funded clinical trials as they are to prescribe drugs from independently funded trials. Indeed, the mere mention of industry turns many physicians off even reading the published studies. These are the take home messages from a study published in the New England Journal of Medicine today.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.